Current sales status of evantumumab in 2025

Amivantamab is a new type of bispecific antibody drug that mainly targets EGFR and MET, two targets closely related to tumorigenesis. It is designed to treat non-small cell lung cancer (NSCLC) related to EGFR gene mutations. Compared with traditional single-target antibody drugs, evantumumab has a more complex and precise mechanism in blocking tumor cell growth signaling pathways, and can simultaneously inhibit drug resistance caused by EGFR activation and MET amplification. Therefore, it is particularly suitable for the treatment of patients who are resistant to EGFR-TKIs, especially those with advanced lung cancer who have EGFR exon20 insertion mutations. Its mechanism of action also includes activating the anti-tumor function of immune cells and improving the clearance ability within the tumor microenvironment, which provides new ideas for the current field of targeted therapy.

Currently, evantumumab has been approved for marketing in many European and American countries, such as the United States and the European Union, and is recommended in relevant guidelines for use in patients with non-small cell lung cancer with specific gene mutation types. In early 2025, the drug has been approved and officially launched in mainland China, marking the entry of domestic lung cancer treatment into a new stage of precision treatment. However, due to the short time to market and the fact that the drug supply chain and medical insurance approval are not yet fully covered, patients nationwide may face inconvenience in purchasing drugs in the short term.

For patients who are in urgent need of medication or want to find alternative purchasing methods, they can currently consider going to regular pharmacies in Hong Kong, China or overseas to obtain the original version of the drug. It is understood that evantumumab has been launched by the original manufacturer in Hong Kong, with a specification of 350mg injection and a price of about RMB 10,000. In the European and American markets, due to different pharmaceutical systems, the price of a single box may be as high as more than RMB 20,000. The specific cost will be affected by exchange rates, regional differences and transportation channels. In addition, no generic versions have yet been approved in India and other places, so the market is still dominated by original drugs.

Reference materials:https://www.rybrevant.com/